



**VENTUREPHARM LABORATORIES LIMITED**

**萬全科技藥業有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 8225)

**INTERIM REPORT 2011  
FOR THE SIX MONTHS ENDED 30 JUNE 2011**

*\*for identification only*

INTERIM REPORT  
FOR THE SIX MONTHS ENDED 30 JUNE 2011

***Characteristics of the Growth Enterprise Market (the “GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”)***

***GEM has been positioned as a market designed to accommodate companies to which a high investment risk may be attached than other companies listed on the Stock Exchange. Prospective investor should be aware of the potential risk of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.***

***Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.***

*The Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This report, for which the directors (the “Directors”) of Venturepharm Laboratories Limited (the “Company”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*



# VENTUREPHARM LABORATORIES LIMITED

## 萬全科技藥業有限公司

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 8225)

The Directors are pleased to announce the unaudited interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2011, together with the comparative figures.

### HIGHLIGHTS

1. The Group achieved a turnover of RMB 24,013,000 for the six months ended 30 June 2011 representing a decrease of approximately 7% compared with that of the corresponding period in 2010. All income except for royalty increased.
2. Due to the efficient cost control, the Group achieved profit from operations of RMB 5,273,000 for the six months ended 30 June 2011, representing an increase of approximately 91% compared with that of the corresponding period in 2010.
3. Basic earnings per share amounted to RMB0.84 cent for the six months ended 30 June 2011.
4. The Group has got 3 new Clinical Study Approval and 1 new Manufacturing Approval by SFDA granted in the past six months of 2011. The total number of Clinical Study Approval has reached 330 and the total number of Manufacturing Approvals has climbed up to 133.
5. The group has made great efforts to collect payments for the six months ended 30 June 2011 and cash balance increased significantly.

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Notes	Unaudited		Unaudited	
		Three months ended 30 June		Six months ended 30 June	
		2011	2010	2011	2010
		RMB'000	RMB'000	RMB'000	RMB'000
Turnover	2	9,513	12,965	24,013	25,790
Cost of sales		<b>(4,343)</b>	(8,043)	<b>(13,093)</b>	(15,663)
Gross profit		<b>5,170</b>	4,922	<b>10,920</b>	10,127
Administrative expenses	3	<b>(2,853)</b>	(4,168)	<b>(5,647)</b>	(7,370)
Profit from operations		<b>2,317</b>	754	<b>5,273</b>	2,757
Other income		<b>1,213</b>	3,220	<b>1,300</b>	3,178
Finance costs		<b>(1,559)</b>	2,191	<b>(2,427)</b>	1,430
Profit before taxation		<b>1,971</b>	6,165	<b>4,146</b>	7,365
Income tax	6	<b>(295)</b>	157	<b>(958)</b>	0
Profit for the year		<b>1,676</b>	6,322	<b>3,188</b>	7,365
Attributable to :					
Equity holders of the Company		<b>1,582</b>	6,174	<b>3,063</b>	7,320
Minority interests		<b>94</b>	148	<b>125</b>	45
Profit for the year		<b>1,676</b>	6,322	<b>3,188</b>	7,365
Earnings per share (cent)					
- basic	5	<b>0.43</b>	1.74	<b>0.84</b>	2.03
- diluted	5	<b>0.43</b>	1.70	<b>0.84</b>	2.01

## CONSOLIDATED BALANCE SHEET

	Notes	Unaudited 30 June 2011 RMB'000	Unaudited 30 June 2010 RMB'000
<b>Non-current assets</b>			
Property, plant and equipment		15,708	9,090
Deferred tax assets		5,340	7,720
New drugs technology			9,203
		21,048	26,013
<b>Current assets</b>			
Work-in-progress		59,170	56,513
Trade receivables		9,324	27,458
Other receivables, deposits and prepayments		16,059	37,059
Financial assets at fair value through profit or loss		57,962	60,308
Cash and cash equivalents		22,689	1,659
		165,204	182,997
<b>Current liabilities</b>			
Trade and other payables		5,704	10,433
Receipt in advance		1,488	782
Income tax liabilities		307	1,501
		7,499	12,716
<b>Net current assets</b>		157,705	170,281
<b>Total assets less current liabilities</b>		178,753	196,294
<b>Non-current liabilities</b>		118,930	76,025
<b>Net assets</b>		59,823	120,269
<b>Capital and reserves</b>			
Share capital			38,469
Reserves		20,122	80,226
		58,653	118,695
Total equity attributable to equity shareholders of the Company		58,653	118,695
<b>Minority interests</b>		1,170	1,574
<b>Total equity</b>		59,823	120,269

## CONDENSED CONSOLIDATED CASH FLOW STATEMENT

---

	Unaudited six months ended 30 June	
	2011	2010
	RMB'000	RMB'000
Net cash used in operating activities	16,208	(12,969)
Net cash used in investing activities	(250)	698
Net cash generated from financing activities	(179)	(157)
Net decrease in cash and cash equivalents	15,779	(12,428)
Cash and cash equivalents at beginning of the period	<u>6,910</u>	<u>14,087</u>
Cash and cash equivalents at end of the period	<u><b>22,689</b></u>	<u><b>1,659</b></u>

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share-		Available-			Statutory				Total
	Based	Share-	for-sales	Special	Capital	Statutory	fund	Retained	Minority	
	Share	Payment	Assets	Reserve	reserve	reserve	expansion	earnings	interest	
	capital	reserve	reserve	Reserve	reserve	reserve	expansion	earnings	interest	
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2010	38,469	2,946	0	6,039	1,459	3,803	6,986	51,825	1,377	112,904
New issue of shares										
Profit for the period	-	-	-	-	-	-	-	7,320	45	7,365
At 30 June 2010	38,469	2,946	0	6,039	1,459	3,803	6,986	59,145	1,422	120,269
At 1 January 2011	38,469	3,627	0	6,039	1,459	3,803	6,986	(5,103)	1,045	56,325
New issue of shares										
	62	-	-	--	248	-	-	-	-	310
Profit for the period	-	-	-	-	-	-	-	3,063	125	3,188
At 30 June 2011	38,531	3,627	0	6,039	1,707	3,803	6,986	(2,040)	1,170	59,823

## **NOTES TO THE FINANCIAL STATEMENTS**

### **1. Accounting policies and basis of preparation**

The unaudited condensed financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs) HKAS 34 Interim Financial Reporting. In addition, the financial statements comply with the applicable disclosure provisions of Rule 18, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The accounting policies adopted are consistent with those followed in the preparation of the Group's audited consolidated financial statements for the year ended 31 December 2010.

The accounts have been prepared on a consolidated basis and include the financial statements of the Company and its subsidiaries made up to 30 June 2011. The measurement basis used in the preparation of the financial statements is historical cost as modified by the revaluation of certain financial assets and liabilities at fair value.



## 2. Turnover and revenue

The Group is principally engaged in the research, development and commercialization of drug products:

Breakdown of the revenue from all services is as follows:

	Unaudited		Unaudited	
	three months ended		six months ended	
	30 June		30 June	
	2011	2010	2011	2010
	RMB' 000	RMB' 000	RMB' 000	RMB' 000
Contracted clinical services outsourced by customers(VPS)	4,988	5,616	14,788	13,396
Contracted pharmaceutical development and services (PDS)	3,012	3,637	7,712	7,037
Import registration services(IRS)	1,000	365	1,000	640
Royalty income		3,200		4,400
Sales of active pharmaceutical ingredients product(API)	513	147	513	317
	<b>9,513</b>	<b>12,965</b>	<b>24,013</b>	<b>25,790</b>

## 3. Administrative expenses

	Unaudited		Unaudited	
	Three months ended 30 June		Six months ended 30 June	
	2011	2010	2011	2010
Notes	RMB'000	RMB'000	RMB'000	RMB'000
Administrative expenses	2,853	4,168	5,647	7,370

Administrative expenses decreased by 23% for the reason of strict cost control.

## 4. Dividends

The board does not recommend the payment of any interim dividend for the six months ended 30 JUNE 2011. (2010: Nil)

## 5. Earnings per share

The calculation of basic earnings per share for the three and six months ended 30 June 2011 is based on the unaudited net profit of approximately RMB1,676,000 and RMB3,188,000 respectively (2010: approximately RMB6,322,000 and RMB7,365,000 respectively), and the weighted average number of approximately 364,243,264 ordinary shares in issue during the period (2010: 363,511,664) .

The calculation of the diluted earnings per share for the three months and six months ended 30 June 2011 is based on the unaudited net profit of approximately RMB1,676,000 and RMB3,188,000 respectively (2010: approximately RMB6,322,000 and RMB7,365,000 respectively), and the weighted average of approximately 364,243,264 shares (2010:approximately 363,511,664) (after adjusting for the effect of the outstanding dilutive options under the share option schemes of the Company).

## 6. Income Taxes

No Hong Kong profit taxes has been provided for, as the Group had no estimated assessable profits in Hong Kong for the period(2010: Nil),

PRC enterprise income tax is calculated and paid at 25% according to Chinese laws and regulations (2010: 25%).

	Unaudited three months		Unaudited Six months	
	Ended 30 June		ended 30 June	
	2011	2010	2011	2010
	RMB' 000	RMB' 000	RMB' 000	RMB' 000
Chinese Income Tax	<b>295</b>	(157)	<b>958</b>	-

## 7. Segment information

No geographical segment analysis is presented as 90% of assets and operations of the Group for the periods are located in the PRC.

## MANAGEMENT DISCUSSION AND ANALYSIS


### FINANCIAL REVIEW

The Group has achieved a turnover of RMB 24,013,000 for the six months ended 30 June 2011, representing a decrease of approximately 7% compared with that of the corresponding period in 2010, of which, contracted clinical service(VPS) achieved RMB14,788,000, increasing by 10.4%, Contracted pharmaceutical development and service(PDS) achieved RMB7,712,000, increasing by 9.6%. Royalty income dropped to zero, whereas, the turnover of which during the corresponding period in 2010 is RMB4,000,000.

### BUSINESS HIGHLIGHTS

The Group has initiated 22 new projects in the past six months of 2011, and till now has 146 products under development. During the period, SFDA has granted 3 new Clinical Study Approval (“CA”) and 1 new Manufacturing Approval (“MA”) to the Group, The total number of CAs has reached to 330 and the total number of MAs has climbed up to 133.

The following graph sets out the total number of CAs and MAs obtained during the recent years:



### PROSPECTS

The company has made best efforts to improve its service capacities and performance in R&D outsourcing service by providing fully integrated pharmaceutical services that include drug discovery, API (Active Pharmaceutical Ingredient), PDS (Pharmaceutical Development Service), Pre-clinical research, CRS (Contract Research Service), RAS (Regulatory Affairs Service), CMS (Contract Manufacturing Service) and CSS (Contract Sales Service). In the meantime, the Group believes that as the government further standardizes and implements its supervision, the market environment will become more favorable to the Group given its competitive edge. Meanwhile, the investment from Chinese government into the scientific research of biologic and pharmaceutical technology will stimulate greatly to the R&D service market. The upcoming new booming age of the pharmaceutical industry will not only present the Group with rare and precious business opportunities, but also considerable return for the shareholders.

## **DIVIDEND**

The Directors have not recommended payment of any interim dividend for the six months ended 30 June 2011.

## **SIGNIFICANT INVESTMENTS**

The Company invested its surplus fund through its principal bank in investment market funds, which was RMB 57,962,000 as at 30 June 2011.

## **CONTINGENT LIABILITIES**

As at 30 June 2011, the Group did not have any contingent liabilities.

## **FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS**

Other than those disclosed in the Company's public announcements, the Group does not have any other plans for material investments or capital assets.

## **CAPITAL STRUCTURE**

There has not been any significant change to the capital structure of the Company since that date.

## **FOREIGN EXCHANGE EXPOSURE**

During the period under review, the Group's transactions were substantially denominated in Renminbi ("RMB"). In view of the RMB appreciation trend, the Group engaged in risk-free value-added banking activities in due course and transferred its USD-denominated businesses to RMB-denominated businesses according to the relevant business scale. The Group closely monitors its foreign currency risk from time to time and will use appropriate hedging when necessary.

## **PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S SHARES**

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed shares during the three months ended 30 June 2011,.

## **COMPETING INTERESTS**

As at 30 June 2011, none of the Directors or the management shareholders of the Company and their respective associates (as defined in the GEM Listing Rules) had any interest in a business that competes or may compete with the business of the Group.

## **CORPORATE GOVERNANCE**

### **(1) Corporate governance practices**

The Company applied the principles and fully complied with the Code Provision as set out in Appendix 15 of the GEM Listing Rules ("CG Code") with certain deviations save as disclosed in respect of the roles of chairman and chief executive officer.

### **(2) Directors' securities transactions**

The Company has adopted the Company Code for Securities Transactions by Directors of Listed Issuers in compliance with the provisions that are set out in the GEM Listing Rules as its own code of conduct for Directors' dealings of securities since 29 June 2005. Specific enquiries have been made with all Directors and the Directors confirmed that they have complied with the required standard set out in the Company Code in the period from 1 January 2011 to 30 June 2011

### **(3) Chairman and chief executive officer**

Chairman of the Board is responsible for the leadership and effective running of the Board, and ensures that all keys and appropriate issues are discussed by the Board in a timely and constructive manner.

However, the Chief Executive of the Company has not yet been appointed. Currently, the day-to-day management of the Company's business is handled by the executive directors and senior management, who take the responsibility to run the Group's business and to implement the Group's strategy so as to achieve the overall commercial objectives of the Company.

### **(4) Board practice and procedures**

During the period from the date of listing to 30 June 2011, the Company has been in compliance with the board practices and procedures as set out in Rule 5.34 of the GEM Listing Rules

### **(5) Audit committee**

The audit committee was established with written terms of reference in compliance with the GEM Listing Rules. The primary duties of the audit committee are to review the Company's annual reports and accounts, half-yearly reports and quarterly reports and internal control system of the Group and provide advice and comments to the Board. The audit committee has three members comprising the three Independent Non-executive Directors, Mr. WANG Hong Bo, Mr. Paul CONTOMICHALOS and Mr. WU Ming Yu. Mr. WANG Hong Bo is the chairman of the audit committee.

The company's financial statements for the six months ended 30 June 2011 have been reviewed by the audit committee.

### **(6) Directors' Acknowledgement of Their Responsibility for the Financial Statements**

The Directors acknowledge that they take full responsibility in the preparation of the financial statements.

**By Order of the Board**  
**William Xia Guo**  
**Chairman**

Beijing, PRC, 13 August 2011

*Executive Directors:*

William Xia GUO

Maria Xuemei SONG

*Non-Executive Directors:*

FENG Tao

WU Xin

Nathan Xin ZHANG

*Independent Non-Executive Directors:*

WANG Hong Bo

Paul CONTOMICHALOS

WU Ming Yu